BioLineRx Ltd. (BLRX)
NASDAQ: BLRX · Real-Time Price · USD
0.336
-0.209 (-38.35%)
Nov 21, 2024, 1:24 PM EST - Market open
BioLineRx Employees
BioLineRx had 79 employees as of December 31, 2023. The number of employees increased by 30 or 61.22% compared to the previous year.
Employees
79
Change (1Y)
30
Growth (1Y)
61.22%
Revenue / Employee
$215,797
Profits / Employee
-$381,253
Market Cap
44.57M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
NeueHealth | 1,252 |
Accelerate Diagnostics | 134 |
iCAD, Inc. | 69 |
AN2 Therapeutics | 41 |
LAVA Therapeutics | 37 |
Reviva Pharmaceuticals Holdings | 15 |
Intensity Therapeutics | 7 |
Nexalin Technology | 6 |
BLRX News
- 6 hours ago - BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd. - PRNewsWire
- 1 day ago - BioLineRx to Report Third Quarter 2024 Results on November 25, 2024 - PRNewsWire
- 16 days ago - BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024 - PRNewsWire
- 5 weeks ago - BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide - PRNewsWire
- 2 months ago - BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection - PRNewsWire
- 3 months ago - BioLineRx Ltd. (BLRX) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates - PRNewsWire
- 3 months ago - BioLineRx to Report Second Quarter 2024 Results on August 15, 2024 - PRNewsWire